Caffeine as a primary neuroprotectice agent for preterm infants




Download 1,5 Mb.
bet85/654
Sana03.01.2022
Hajmi1,5 Mb.
#14803
1   ...   81   82   83   84   85   86   87   88   ...   654
Caffeine as a primary neuroprotectice agent for preterm infants:By definition, neuroprotection is an effect that may result in salvage, recovery or regeneration of the nervous system, its cells, structure and function.[25] Routine use of caffeine as a neuroprotective agent in preterm infants (non-ventilated with no history of apneas) has not been proven.

References

1. Brattstrom P, Russo C, Ley D, Bruschettini M. High-versus low-dose caffeine in preterm infants: a systematic review and meta-analysis. Acta Paediatrica, International Journal of Paediatrics. 2019;108:401-10.

2. Eichenwald EC, Committee on F, Newborn AAoP. Apnea of Prematurity. Pediatrics. 2016;137.

3. Rostas SE, McPherson C. Caffeine Therapy in Preterm Infants: The Dose (and Timing) Make the Medicine. Neonatal network : NN. 2019;38:365-74.

4. Charles BG, Townsend SR, Steer PA, Flenady VJ, Gray PH, Shearman A. Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. Ther Drug Monit. 2008;30:709-16.

5. Lee TC, Charles B, Steer P, Flenady V, Shearman A. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther. 1997;61:628-40.

6. Doyle J, Davidson D, Katz S, Varela M, Demeglio D, DeCristofaro J. Apnea of prematurity and caffeine pharmacokinetics: Potential impact on hospital discharge. Journal of Perinatology. 2016;36:141-4.

7. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W. Caffeine therapy for apnea of prematurity. The New England journal of medicine. 2006;354:2112-21.

8. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W.Long-term effects of caffeine therapy for apnea of prematurity. The New England journal of medicine. 2007;357:1893-902.

9. Murner-Lavanchy IM, Doyle LW, Schmidt B, Roberts RS, Asztalos EV, Costantini L, et al. Neurobehavioral outcomes 11 years after neonatal caffeine therapy for apnea of prematurity. Pediatrics. 2018;141 (5) (no pagination).

10. HendersonSmart DJ, De Paoli AG. Prophylactic methylxanthine for prevention of apnoea in preterm infants. Cochrane Database of Systematic Reviews. 2013.

11. Vliegenthart R, Miedema M, Hutten GJ, van Kaam AH, Onland W. High versus standard dose caffeine for apnoea: a systematic review. Arch Dis Child Fetal Neonatal Ed. 2018;103:F523-F9.

12. Chen J, Jin L, Chen X. Efficacy and safety of different maintenance doses of caffeine citrate for treatment of apnea in premature infants: A systematic review and meta-analysis. BioMed Research International. 2018;2018 (no pagination).

13. Henderson-Smart DJ, Steer P. Prophylactic caffeine to prevent postoperative apnea following general anesthesia in preterm infants. Cochrane database of systematic reviews. 2001:CD000048.

14. Massoud M, Kuhlmann AYR, Van Dijk M, Staals LM, Wijnen RMH, Van Rosmalen J, Sloots CEJ, Keyzer-Dekker CMG. Does the incidence of postoperative complications after inguinal hernia repair justify hospital admission in prematurely and term born infants? Anesthesia and Analgesia. 2019;128:525-32.

15. Kua KP, Lee SWH. Systematic review and meta-analysis of clinical outcomes of early caffeine therapy in preterm neonates. British Journal of Clinical Pharmacology. 2017;83:180- 91.

16. Park HW, Lim G, Chung SH, Chung S, Kim KS, Kim SN. Early Caffeine Use in Very Low Birth Weight Infants and Neonatal Outcomes: A Systematic Review and Meta-Analysis. Journal of Korean medical science. 2015;30:1828-35.

17. HendersonSmart DJ, Davis PG. Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane Database of Systematic Reviews. 2013.

18. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for endotracheal extubation in preterm infants. Cochrane database of systematic reviews. 2010:CD000139.

19. Khurana S, Shivakumar M, Sujith Kumar Reddy GV, Jayashree P, Ramesh Bhat Y, Lewis LES, Shashikala. Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. Journal of Neonatal-Perinatal Medicine. 2017;10:355-62.

20. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A, Plavka R, Roehr CC, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GHA, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 2019;115:432-50.

21. McPherson C, Neil JJ, Tjoeng TH, Pineda R, Inder TE. A pilot randomized trial of high-dose caffeine therapy in preterm infants. Pediatr Res. 2015;78:198-204.

22. Vesoulis ZA, McPherson C, Neil JJ, Mathur AM, Inder TE. Early High-Dose Caffeine Increases Seizure Burden in Extremely Preterm Neonates: A Preliminary Study. Journal of Caffeine Research. 2016;6:101-7.






Original version Date: 08/08/2015

Author: NeoMed Consensus Group

Current Version number: 3

Version Date: Jan 2020

Risk Rating: Medium

Due for Review: Jan 2025

Approval by: DTC

Approval Date: Jan 2020




Download 1,5 Mb.
1   ...   81   82   83   84   85   86   87   88   ...   654




Download 1,5 Mb.

Bosh sahifa
Aloqalar

    Bosh sahifa



Caffeine as a primary neuroprotectice agent for preterm infants

Download 1,5 Mb.